

To,
The Board of Directors,
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Mumbai

Dear Sir,

Re: Limited Review of Un-audited Financial Results for the Half Year ended 31st March, 2017 in respect of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Introduction

We have reviewed the accompanying statement of unaudited financial results of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) for the half year ended **31st March, 2017** this statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a Report on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review of Interim Financial Information performed issued by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS**

Firm Registration No. 109901W/W100082

Sd/-

SATISH JAIN

**PARTNER
M. No. 048874**

Place : MUMBAI

Dated : 23/01/2018

Genlink Pharma Solutions Pvt. Ltd.
(Formerly known as Genlink Pharma Investments Pvt. Ltd.)
CIN: U74110 MH 2016 PTC 280765

Statement of standalone financial results for the half year ended March 31, 2017

INR

PARTICULARS	Six Months ended 31-March-2017 Unaudited	Preceding Six Months ended 30-Sept-16 Unaudited	Previous year ended 31-March-17 Audited
1 Income from Operations			
a Net Sales / Income from Operations (net of excise duty)	1,750,000	-	1,750,000
b Other Operating Income	-	-	-
Total Income from Operations (net)	1,750,000	-	1,750,000
2 Expenses			
a Cost of Materials consumed	-	-	-
b Purchase of stock-in-trade	-	-	-
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-
d Employee benefit expenses	-	-	-
e Depreciation and amortization expense	-	-	-
f Other expenses	1,779,622	115,263	1,894,885
Total Expenses	1,779,622	115,263	1,894,885
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	-29,622	-115,263	-144,885
4 Other Income	-	-	-
5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3-4)	-29,622	-115,263	-144,885
6 Finance Cost	1,533,783	4,482	1,538,265
7 Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5-6)	-1,563,405	-119,745	-1,683,150
8 Exceptional Items	-	-	-
9 Profit/(Loss) from ordinary activities before tax (7-8)	-1,563,405	-119,745	-1,683,150
10 Tax Expense	531,830	-	531,830
11 Net Profit/(Loss) from ordinary activities after tax (9-10)	-2,095,235	-119,745	-2,214,980
12 Extraordinary items (net of tax INR expense lacs)			
13 Net Profit / Loss for the period (11-12)	-2,095,235	-119,745	-2,214,980
14 Paid up equity share capital (Face value of the share shall be indicated)	100,000	100,000	100,000
15 Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-2,095,235	-119,745	-2,214,980
16.i Earnings Per Share (before extraordinary items) (of INR /- each) (not annualized):			

a	Basic	-231.75	-13.24	-244.99
b	Diluted	-231.75	-13.24	-244.99
16.ii	Earnings Per Share (after extraordinary items) (of INR /- each) (not annualized):			
a	Basic	-231.75	-13.24	-244.99
b	Diluted	-231.75	-13.24	-244.99

Note

The financial year 2016-2017 is the first financial year of the Company.

For Shankarlal Jain & Associates LLP
Chartered Accountants
Bomble
Registration No. 109901W/W100082
Financial Officer
Sd/-
Satish Jain
Partner
Membership no. 048874
Mumbai
Date: 23.01.2018

For Genlink Pharma Solutions Private Limited
Anand Shah Susheel Koul Somnath
Director Managing Director Chief
DIN 00597145 DIN 00925887
Navi Mumbai Navi Mumbai

Statement of Assets and Liabilities for Companies

**Standalone Statement of Assets and Liabilities
Particulars**

A EQUITY AND LIABILITIES

1 Shareholders' funds

(a) Share capital

(b) Reserves and surplus

(c) Money received against share warrants

Sub-total - Shareholders' funds

	INR	
	As at half year end 30-Sept-16 Unaudited	As at year end 31-March-17 Audited
	100,000	100,000
	-119,745	-2,214,980
	-	-
	-19,745	-2,114,980

2. Share application money pending allotment

3. Non-current liabilities

(a) Long-term borrowings	-	250,000,000
(b) Deferred tax liabilities (net)	-	-
(c) Other long-term liabilities	-	-
(d) Long-term provisions	-	-
Sub-total - Non-current liabilities	-	250,000,000

4. Current liabilities

(a) Short-term borrowings	87,577	-
(b) Trade payables	6,448	-
(c) Other current liabilities	-	1,817,241
(d) Short-term provisions	35,482	408,830
Sub-total - Current liabilities	129,507	2,226,071

TOTAL - EQUITY AND LIABILITIES

109,762 250,111,091

B ASSETS

1. Non-current assets

(a) Fixed assets	-	-
(b) Non-current investments	-	248,995,479
(c) Deferred tax assets (net)	-	-
(d) Long-term loans and advances	-	-
(e) Other non-current assets	-	-
Sub-total - Non-current assets	-	248,995,479

2 Current assets

(a) Current investments	-	-
(b) Inventories	-	-
(c) Trade receivables	-	-
(d) Cash and cash equivalents	109,762	1,115,612
(e) Short-term loans and advances	-	-
(f) Other current assets	-	-
Sub-total - Current assets	109,762	1,115,612

TOTAL - ASSETS

109,762 250,111,091

For Shankarlal Jain & Associates LLP
Chartered Accountants
Bomble
Registration No. 109901W/W100082
Financial Officer
Sd/-
Satish Jain
Partner
Membership no. 048874
Mumbai
Date: 23.01.2018

For Genlink Pharma Solutions Private Limited
Anand Shah Susheel Koul Somnath

Director Managing Director Chief

DIN 00597145 DIN 00925887
Navi Mumbai Navi Mumbai